AsymBio to secure $184m to support growth in biologics manufacturing

Salong Debbarma

Wed, August 5, 2026 astatine 4:59 AM CDT 1 min read

Biologics declaration improvement and manufacturing organisation (CDMO) AsymBio is acceptable to unafraid 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and different investors to enactment its semipermanent growth.

The funds volition beryllium utilized for AsymBio's main concern operations and thrust further enlargement of its manufacturing capacity.

Asymchem Group volition lend 1.05bn yuan portion Hillhouse Qirui volition put 177m yuan.

Following the transaction, Asymchem Group's shareholding successful AsymBio is acceptable to emergence to 83.4965%.

Hillhouse Qirui's concern is described arsenic reflecting semipermanent assurance successful some AsymBio and the wider biologics CDMO sector.

The financing circular besides brings unneurotic different unnamed investors and is said to align with Asymchem Group's strategical attack of providing "one-stop, end-to-end CDMO" services.

The further superior comes arsenic AsymBio expands its probe and improvement capabilities, bully manufacturing signifier (GMP) manufacturing lines, and high-containment facilities.

The institution states that the caller backing volition beryllium directed towards supporting the scaling of lawsuit programmes and expanding operational efficiency.

Financial results released by AsymBio bespeak that the institution generated 470m yuan successful gross during 2025, with gross for the archetypal 4th of 2026 exceeding 140m yuan.

AsymBio operates arsenic a subsidiary of Asymchem Group and focuses connected biopharmaceutical CDMO services, ranging from early-stage and process improvement to toxicology, clinical, and large-scale commercialized manufacturing.

The radical points to its acquisition successful the accumulation of antibody-drug conjugates (ADCs) and ongoing enlargement into caller cause conjugates (NDCs) and assorted protein-based therapeutics.

"AsymBio to unafraid $184m to enactment maturation successful biologics manufacturing" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.